Heartflow filed a lawsuit against Cleerly in the United States District Court for the Eastern District of Texas, alleging that Cleerly’s Ischemia, Plaque Analysis, and Compare products infringe six of Heartflow’s patents that date from 2012 to 2018. The complaint was filed on April 13 2026.
The patents cover core components of Heartflow’s AI‑driven coronary artery disease detection platform, which the company has been developing since 2010. Heartflow maintains a portfolio of more than 600 granted patents worldwide, positioning it as a pioneer in non‑invasive coronary artery disease diagnostics.
Cleerly, a competitor that launched its Ischemia, Plaque Analysis, and Compare products in 2024, has secured $106 million in Series C funding and recently achieved Medicare coverage for its advanced plaque analysis. The lawsuit could limit Cleerly’s ability to market these products and expose the company to significant damages.
Heartflow’s CEO John Farquhar said, “Heartflow pioneered a significant medical technology that has touched over 600,000 patients’ lives. Our team has worked tirelessly since 2010 to develop the Heartflow Platform, a first‑of‑its‑kind AI solution that has been used to detect and manage coronary artery disease. We take seriously our responsibility to protect the intellectual property that supports this field and the clinicians and patients it serves.” The filing underscores Heartflow’s commitment to defending its IP and maintaining its competitive edge.
The lawsuit comes amid strong financial performance for Heartflow, which reported Q4 2025 revenue of $49.1 million, a 40 % year‑over‑year increase to $176 million for the full year, and guidance that topped consensus estimates. Aetna’s nationwide coverage of Heartflow’s plaque analysis has expanded the platform’s reach to roughly 75 % of U.S. insured lives, providing a commercial catalyst that the company highlighted in its earnings release.
Investors are monitoring the case for its potential legal costs and the impact on Cleerly’s growth trajectory. The outcome could reshape the competitive landscape for AI‑driven cardiovascular diagnostics and influence future patent litigation in the sector.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.